ft500

Advanced Solid Tumors

Fate TherapeuticsPhase 1Dormant

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 59/ 100

Competitive context

1412 Active assets in the Advanced Solid Tumors cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

ft500 is also rated in:

EGFR Positive Solid TumorDormant

CC

Indicative ·

47 / 100

Microsatellite InstabilityDormant

CC

Indicative ·

47 / 100

cutaneous neuroendocrine carcinomaDormant

CC

Indicative ·

44 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.